NPI | Name | Type | Address |
---|---|---|---|
DR. PHARM.D, Nina Dipierro |
Individual |
160 E 53rd St New York, NY |
|
Meagan Griffin |
Individual |
1275 York Ave New York, NY |
|
PHARMD Kristen Marie Poppiti |
Individual |
1250 1st Ave Schwartz 710 New York, NY |
|
PHARM.D Dazhi Liu |
Individual |
1275 York Ave New York, NY |
|
DR. PHARMD Carmen Lau |
Individual |
1275 York Avenue Schwartz-710 New York, NY |
|
DR. PHARMD Bernadette Catherine Loughlin |
Individual |
1275 York Ave Room C-1087 New York, NY |
|
PHARM.D. V Park |
Individual |
405 Lexington Ave New York, NY |
|
DR. PHARMD Brianne Dixon |
Individual |
1275 York Ave New York, NY |
|
DR. PHARMD Jeremy Pappacena |
Individual |
1275 York Ave New York, NY |
|
PHARMD Charlene Claire Kabel |
Individual |
1275 York Ave New York, NY |
|
PHARM.D. Maxwell Alexander Brown |
Individual |
525 E 68th St Rm K04 New York, NY |
|
PHARMD Terry Kheng Pak |
Individual |
1275 York Ave Ste 712 New York, NY |
|
PHARMD Bradley Figgins |
Individual |
1275 York Ave New York, NY |
|
DR. PHARMD Michael John Buege |
Individual |
1275 York Ave New York, NY |
|
DR. PHARMD Michelle Pasciolla |
Individual |
525 E 68th St New York, NY |
|
Raymond Dematteo |
Individual |
1275 York Ave New York, NY |
|
PHARMD Shaziya Barkat |
Individual |
1275 York Ave New York, NY |
|
MS. Melonie Devi Sanassy |
Individual |
300 E 66th St New York, NY |
|
DR. Taylor Mai Weis |
Individual |
1275 York Ave New York, NY |
|
DR. PHARMD Shelby Lorraine Merchant |
Individual |
1275 York Ave New York, NY |
Every health care provider, whether it’s a hospital, pharmacy, or individual specialist, must obtain their own NPI number. This identification number is unique and is assigned upon application. In tod...
Taxonomy Code | 1835X0200X |
Specialization | Oncology |
Display Name | Oncology Pharmacist |
Taxonomy Group | Pharmacy Service Providers |
Taxonomy Classification | Pharmacist |
Definition | A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases. |
Effective Date | September 30, 2009 |